<DOC>
	<DOCNO>NCT03003039</DOCNO>
	<brief_summary>The purpose study area curve ( AUC ) GB241 rituximab concentration .</brief_summary>
	<brief_title>A Study Comparing GB241 And Rituximab Patients With B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>histologically confirm NHL express CD20 antigen obtain CR ( complete remission ) CRu ( uncertain complete remission ) prior therapy sign informed consent form approve institutional review board respective medical center age 18 75 year ECOG performance status 0 1 expect survival least ≥ 3 month receive rituximab antiCD20 ( + ) monoclonal antibody treatment within 1 year enrollment least 4 week beyond prior anticancer therapy include corticosteroid , recover significant toxicity prior therapy participate clinical trial within 30 day enrolment serious hematologic dysfunction ( white blood cell count &lt; 3.0×103/uL ; absolute neutrophil count &lt; 1.5×103/ uL ; platelet count &lt; 75×103/uL ; hemoglobin level &lt; 8.0 g/dL ) ; hepatic dysfunction ( total bilirubin level &gt; 1.5×ULN ; aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) level &gt; 2.5 × ULN ; renal dysfunction ( serum creatinine level &gt; 1.5×ULN ) ; International normalize ratio ( INR ) partial thromboplastin time activate partial thromboplastin time ( aPTT ) &gt; 1.5 × ULN ( unless therapeutic coagulation ) receive live vaccine within 4 week prior study entry malignancy ; central nervous system ( CNS ) lymphoma , AIDSrelated lymphoma ; active opportunistic infection , serious nonmalignant disease seropositive HCV antibody , HIV antibody , hepatitis B virus surface antigen ( HBsAg ) . HBc antibody seropositive , HBV DNA HBsAg negative patient may participle follow consultation hepatitis expert regard monitoring use HBV antiviral therapy , provide agree receive treatment indicate recent major surgery ( within 28 day prior study entry ) history allergic reaction protein product allergy include murine protein pregnant lactate accepted birth control method include male patient patient consider unsuitable PI previous malignant tumor except cured cervical cancer , basal cell carcinoma squamous cell skin cancer active opportunistic infection serious non neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>GB241</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-cell Lymphoma</keyword>
</DOC>